Related Experiment Video
Updated: Jun 18, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
BmKCT toxin inhibits glioma proliferation and tumor metastasis
Shaozhong Fan1, Zhengbo Sun, Dahe Jiang
1State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei, 430072, PR China.
Abstract:
Malignant gliomas are the most common primary brain tumors associated with significant morbidity and mortality. How to target the tumor in situ, and inhibit tumor cell proliferation and invasion is the key for therapy. Gliomas express a glioma-specific chloride ion channel that is sensitive to toxins including BmKCT. In the current study, the inhibitory effect of BmKCT on glioma growth was observed in vivo using the glioma/SD rat model. Furthermore, BmKCT prevented the metastasis of glioma cells in vivo. Moreover, biodistribution experiments with (l3l)I-labeled or Cy5.5-conjugated BmKCT revealed that BmKCT selectively targeted the glioma in situ. Our data suggest that BmKCT could be exploited as a potential therapeutic for glioma diagnosis and therapy.
Insights
This study shows that BmKCT toxin can inhibit malignant glioma growth and prevent metastasis in rats. BmKCT selectively targets brain tumors, suggesting its potential for glioma diagnosis and therapy.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Pharmacology
Background:
- Malignant gliomas are aggressive primary brain tumors with poor prognoses.
- Targeting tumor cells in situ and inhibiting their proliferation and invasion are critical therapeutic challenges.
- Gliomas possess a unique chloride ion channel sensitive to toxins like BmKCT.
Purpose of the Study:
- To investigate the therapeutic potential of BmKCT against malignant gliomas.
- To evaluate the efficacy of BmKCT in inhibiting glioma growth and metastasis in vivo.
- To determine the tumor-targeting capability of BmKCT.
Main Methods:
- In vivo studies using a glioma/SD rat model to assess BmKCT's effect on tumor growth and metastasis.
- Biodistribution experiments utilizing (131I)-labeled or Cy5.5-conjugated BmKCT to track its localization.
- Assessment of BmKCT's inhibitory effects on glioma cell proliferation and invasion.
Main Results:
- BmKCT demonstrated significant inhibition of glioma growth in vivo.
- BmKCT effectively prevented the metastasis of glioma cells.
- Biodistribution studies confirmed selective targeting of gliomas by BmKCT in situ.
Conclusions:
- BmKCT exhibits potent anti-glioma activity, inhibiting both primary tumor growth and metastasis.
- Selective glioma targeting by BmKCT supports its potential as a diagnostic and therapeutic agent.
- BmKCT represents a promising candidate for novel glioma treatment strategies.
